ArticleBioengineering (Basel, Switzerland)2022
Indirect 3D Bioprinting of a Robust Trilobular Hepatic Construct with Decellularized Liver Matrix Hydrogel.
Article in Bioengineering (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- From scaffold to function: A systematic review on dLECM-based hydrogels for liver tissue engineering - Fabrication, properties, and translational applications.Regenerative therapy · 2026Review
- Designing Porosity-Tailored Hydrogel Sponges with Controlled Cell Positioning Using Dispersible, Autofragmented Sacrificial Microfibers.ACS omega · 2025Article
- Kidney-Derived ECM Hydrogels as Cell Delivery Devices.ACS applied materials & interfaces · 2025Article
- Three-Dimensional Printing/Bioprinting and Cellular Therapies for Regenerative Medicine: Current Advances.Journal of functional biomaterials · 2025Review
- Decellularized Liver Matrices for Expanding the Donor Pool-An Evaluation of Existing Protocols and Future Trends.Biomolecules · 2025Review
- The sculpting tool in bioprinting: research and application progress of sacrificial inks.Frontiers in bioengineering and biotechnology · 2025Review
- Review
- Recent Advances in the Application of 3D-Printing Bioinks Based on Decellularized Extracellular Matrix in Tissue Engineering.ACS omega · 2024Review
- Review
- Tyrosinases: a family of copper-containing metalloenzymes.Chemtexts · 2024Article
- Three Dimensional Bioprinting for Hepatic Tissue Engineering: From In Vitro Models to Clinical Applications.Tissue engineering and regenerative medicine · 2024Review
- Advances in 3D bioprinting for regenerative medicine applications.Regenerative biomaterials · 2024Review
- Tissue Bioprinting: Promise and Challenges.Bioengineering (Basel, Switzerland) · 2023Article
- Recent advances of three-dimensional bioprinting technology in hepato-pancreato-biliary cancer models.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
The liver exhibits complex geometrical morphologies of hepatic cells arranged in a hexagonal lobule with an extracellular matrix (ECM) organized in a specific pattern on a multi-scale level. Previous studies have utilized 3D bioprinting and microfluidic perfusion systems with various biomaterials to develop lobule-like constructs. However, they all lack anatomical relevance with weak control over the size and shape of the fabricated structures. Moreover, most biomaterials lack liver-specific ECM components partially or entirely, which might limit their biomimetic mechanical properties and biological functions. Here, we report 3D bioprinting of a sacrificial PVA framework to impart its trilobular hepatic structure to the decellularized liver extracellular matrix (dLM) hydrogel with polyethylene glycol-based crosslinker and tyrosinase to fabricate a robust multi-scale 3D liver construct. The 3D trilobular construct exhibits higher crosslinking, viscosity (182.7 ± 1.6 Pa·s), and storage modulus (2554 ± 82.1 Pa) than non-crosslinked dLM. The co-culture of HepG
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.